Concurrent Investment Advisors LLC Sells 4,840 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Concurrent Investment Advisors LLC cut its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 26.8% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 13,226 shares of the company’s stock after selling 4,840 shares during the period. Concurrent Investment Advisors LLC’s holdings in Hims & Hers Health were worth $244,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Swiss National Bank boosted its stake in shares of Hims & Hers Health by 0.7% in the first quarter. Swiss National Bank now owns 281,500 shares of the company’s stock worth $4,355,000 after acquiring an additional 2,000 shares during the period. Sei Investments Co. raised its stake in Hims & Hers Health by 206.9% in the first quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock worth $869,000 after buying an additional 37,890 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of Hims & Hers Health during the first quarter valued at about $228,000. Avantax Advisory Services Inc. acquired a new stake in shares of Hims & Hers Health in the 1st quarter worth $156,000. Finally, ProShare Advisors LLC increased its stake in Hims & Hers Health by 10.0% during the 1st quarter. ProShare Advisors LLC now owns 22,257 shares of the company’s stock valued at $344,000 after purchasing an additional 2,023 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Wall Street Analysts Forecast Growth

HIMS has been the topic of several research reports. Piper Sandler reiterated a “neutral” rating and issued a $21.00 price target (up previously from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. Bank of America increased their target price on shares of Hims & Hers Health from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Canaccord Genuity Group increased their target price on Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Finally, Truist Financial raised their price target on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, July 18th. Eight analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $21.21.

Hims & Hers Health Stock Up 19.1 %

HIMS opened at $27.89 on Tuesday. The business has a fifty day simple moving average of $19.01 and a 200-day simple moving average of $18.60. Hims & Hers Health, Inc. has a 52 week low of $6.68 and a 52 week high of $29.68. The firm has a market cap of $5.99 billion, a P/E ratio of 63.38 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. During the same quarter in the previous year, the business posted ($0.04) EPS. The firm’s revenue was up 77.1% on a year-over-year basis. Sell-side analysts expect that Hims & Hers Health, Inc. will post 0.25 earnings per share for the current year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the completion of the sale, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at approximately $487,789.12. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the sale, the chief executive officer now owns 33,502 shares of the company’s stock, valued at $487,789.12. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Soleil Boughton sold 2,345 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $14.65, for a total value of $34,354.25. Following the completion of the sale, the insider now directly owns 159,796 shares in the company, valued at $2,341,011.40. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 854,547 shares of company stock valued at $15,987,230 over the last ninety days. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.